Get started
Author

Kaoru Funabashi

Observed name: K. Funabashi
OpenAlex ID: A5067333314
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2020 · Hiroshi Sootome, Hidenori Fujita, et al. · Cancer Research · 215
PDF
In Vitro Biological Profile of a Highly Potent Novel Endothelin (ET) Antagonist BQ-123 Selective for the ETA Receptor
1992 · Masaki Ihara, Kiyofumi Ishikawa, et al. · Journal of Cardiovascular Pharmacology · 116
TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2019 · Hibiki Udagawa, Shinichi Hasako, et al. · Molecular Cancer Research · 76
Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H -pyrazol-4-yl)-1 H -imidazol-1-yl)-1 H -pyrazolo[3,4- b ]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor
2018 · Takao Uno, Yuichi Kawai, et al. · Journal of Medicinal Chemistry · 61
Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop Phosphorylation
2009 · Tomoko Sunami, Noel Byrne, et al. · Journal of Biological Chemistry · 57
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use
2023 · Satoru Ito, Sachie Otsuki, et al. · ACS Medicinal Chemistry Letters · 50
PDF
Two Endothelin Receptor Subtypes in Porcine Arteries
1991 · M. Ihara, T. Saeki, et al. · Journal of Cardiovascular Pharmacology · 49
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 47
PDF
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2019 · Hiroki Irie, Kimihiro Ito, et al. · Molecular Cancer Therapeutics · 15
TAS2940 , a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations
2022 · Kei Oguchi, Hikari Araki, et al. · Cancer Science · 12
PDF
d-Aspartyl residue in a peptide can be liberated and metabolized by pig kidney enzymes
1996 · Y. Kera, K. Funabashi, et al. · Amino Acids · 6
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 1
PDF
Data from Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
2023 · Hiroshi Sootome, Hidenori Fujita, et al. · 1
Abstract 4784: TAS0286/HM05, a novel highly selective RET inhibitor, prominently inhibits various RET defective tumor growth
2018 · Hidenori Fujita, Isao Miyazaki, et al. · Cancer Research · 1
Abstract 4008: TAS2940, a novel brain-penetrable pan-ERBB inhibitor, exhibits tumor regression and prolongs survival in intracranial models bearing ERBB aberrations
2023 · Kei Oguchi, Hikari Araki, et al. · Cancer Research
Tables S1-3 and Figures S1-4 from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2023 · Hibiki Udagawa, Shinichi Hasako, et al.
PDF
Tables S1-3 and Figures S1-4 from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2023 · Hibiki Udagawa, Shinichi Hasako, et al.
Data from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Data from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
2023 · Hibiki Udagawa, Shinichi Hasako, et al.
Table S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Figure S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Figure S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Table S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Table S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Table S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Works count: 33
Citation count: 707
H-index: 10
I10-index: 10
Year
Topic
Type